Answer
No, the safety and efficacy of erdafitinib have not been established in paediatric patients under 18 years of age.
Sources for this answer
- Balversa 3mg film-coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.2 Posology and method of administration · Version 3Document updated
Sources checked